Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- GENERICS NEWS IN BRIEF
September 22, 2008
- NovoRapid 30 Mix Decreases HbA1c without Increasing Incidence of Serious Hypoglycemic Events
September 22, 2008
- BUSINESS NEWS IN BRIEF
September 22, 2008
- Saxagliptin Effective in Combination with Other Oral Antidiabetic Agents
September 22, 2008
- Japanese Pharma Industry Group Visits UCB
September 22, 2008
- RAD001 Granted Priority Review Status in the US
September 22, 2008
- Meiji Seika, Meiji Dairy to Integrate Businesses
September 22, 2008
- Will Distribution Practices Be Improved? Part 2
September 22, 2008
- NovoRapid 30 Mix Has Turned Out to Be Global Blockbuster: Novo Nordisk Pharma
September 22, 2008
- Loxonin Tape Leads Rep Track Survey Ranking in July
September 15, 2008
- AIDS Drugs Effective against Resistant Virus Needed
September 15, 2008
- Yamato Will Not Be Able to Be Profitable with Generics Alone: Mr Kumakura
September 15, 2008
- Publicity on Effective Migraine Treatment Needed: GSK Seminar
September 15, 2008
- Will Distribution Practices Be Improved? Part 1
September 15, 2008
- Next Generation of Antidiabetic Drugs Discussed: Tokyo Seminar
September 15, 2008
- Suzuken Expects Price Settlement Rate of Over 70% at the End of September
September 15, 2008
- No Subjective Symptoms in 27% of Glaucoma Patients with Impairment of Half of Visual Field
September 15, 2008
- World's 1st Drug for Idiopathic Pulmonary Fibrosis Recommended for Approval
September 15, 2008
- Shionogi to Enter US Market by Acquiring Sciele
September 15, 2008
- DSP to Design Independent US Marketing System by Mid-2009
September 15, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…